Step 5: Ongoing care and refills
Both times are highly effective
However, this approach carries several risks
discussed potential projects with and has signed/signs contracts for his institute(s) and for the staff for research funding and/or collaborations with industries and academia worldwide, including, but not limited to, pharmaceutical corporations like Boehringer Ingelheim, Eli Lilly, Novo Nordisk, Medigene, Arbormed, BioSyngen and others
36 FAQ What is the Biosimilar Paradox mentioned in industry reports
The same letter makes clear the peptides do not automatically move into Category 1 the bucket where the FDA has said it generally would not take action against compounders and that the Pharmacy Compounding Advisory Committee (PCAC) will review them at the July 2324, 2026 meeting, with February 2027 as the alternate date